TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of pediatric patients with one or more exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Synchrony rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Transcutaneous PCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Transcutaneous PO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: treatment success in both eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower total microparticle concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher EPC numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower superoxide dismutase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of fetal mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Genetic outcomes
Primary endpoint: Physical activity intentions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric rating scale scores for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unprotected sex in the last sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unprotected sex in the past 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tandem walk improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intramuscular lipid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscular strength measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC for aliskiren
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Cmax for aliskiren
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean t1/2 for aliskiren
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak H-reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plantar flexion torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: decreased risk of major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of oedema within 2 days after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Need for rescue ranibizumab
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Excess mortality in bolus arms versus control
Endpoint domain: Mortality/survival
Primary endpoint: 1-repetition-maximum ankle-evertor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: peroneus longus muscle latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Grade II GIT symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Average waiting time for walk-in patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients seen within 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-hour pain relief rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-free rates at 2 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained freedom from pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of sufentanil used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete aneurysm occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: adequate occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: primary safety event
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody responses above protective levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measured visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: anxiety score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: irritability score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-week abstinence rate
Endpoint domain: Mortality/survival
Primary endpoint: Prevention of recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression from occasional and experimental smoking to established use
Endpoint domain: Mortality/survival
Primary endpoint: Health Assessment Questionnaire (HAQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of rheumatoid arthritis (RA)
Endpoint domain: Mortality/survival
Primary endpoint: Bronchial symptoms (cough, wheezing, breathlessness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nasal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rates of susceptibility to tobacco use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of tobacco use among youth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative urine excretion of trifluoroacetic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative urine excretion of fluoride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in primary outcome measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal levels of L. rhamnosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal levels of L. acidophilus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean ICA-IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum ICA-IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum plaque height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean decrease in PANSS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting mean glucose change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of esophagogastral mucosal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduced need for procinetic medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Days without symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of exacerbation-free patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stone Free Rate (SFR) at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for auxiliary procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: clinically important pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: color coefficient and absorption spectrum values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hyperactivity, impulsivity and impaired socialization symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative volume values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative density values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platform usage associated with RC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum urine flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prostate size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Need for re-intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: shoulder tip pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of perinatal transmission
Endpoint domain: Mortality/survival
Primary endpoint: Polymerase chain reaction-undetectable viremia at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of elevated ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean reduction in HbA(1c) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean reduction in insulin requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stigmatized behaviors
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Reduction in LDL‐MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in ox‐LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in percentage increase in ACI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum hold time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tumor size from baseline at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior intertrochanteric ossifications (AIO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting GLP-1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incremental response in GLP-1 during OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma concentrations of glucose and insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum alpha‐tocopherol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum beta‐carotene levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum vitamin C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum selenium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GPx activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute VO2peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 150 kJ time trial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Locus length per unit area (L/A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Envelope area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol responsivity to acute uncontrollable psychosocial stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in PLMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in sleep efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-confidence in H&P skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma ACTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Flight performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: IPC as a predictor of platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of IL-1Ra
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of clinical pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Retention rate
Endpoint domain: Resource use
Endpoint subdomain: null
Primary endpoint: Proportion of product use during 100% of acts with casual partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported genitourinary symptoms
Endpoint domain: Adverse events/effects
Endpoint subdomain: null
Primary endpoint: Percentage of patients with > or =70% stenosis of the ipsilateral carotid artery at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of restenosis to > or =70% stenosis between 1 month and 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of recurrent ipsilateral symptoms at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Statistically significant decrease in SBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Statistically significant decrease in BANA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Statistically significant decrease in PLI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Oxidative stress levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiopulmonary resuscitation performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAHPS satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: homologous transfusions
Endpoint domain: Adverse events/effects
Primary endpoint: lengths of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total CABG surgery cost reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CVICU costs reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Elective case cancellations reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Perceived energy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motivation to exercise
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Focus
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Paresthesia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory depression identified by ETCO2 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mortality rates at 10 months
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of moderate vertigo episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe vertigo episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gorlin mitral valve area (MVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Residual mitral stenosis (MVA <1.5 cm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from reintervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Compliance with HRT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: two-year all-cause mortality or new Q-wave myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: BARC-defined bleeding type 3/5
Endpoint domain: Adverse events/effects
Primary endpoint: Full desensitization to sesame
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactions to doses
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in rSes i 1 IgE and IgG4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Attendance at follow-up workshops
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sharing information from Project HEAL
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Continuation of health activities in churches
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: NRS (Numeric Rating Scale) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tobacco withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall self-efficacy improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: visual field status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: localized deterioration
Endpoint domain: Adverse events/effects
Primary endpoint: Lipoprotein subclasses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mRNA levels of LXRA and LDLR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA levels of UCP2 and PPARD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exclusive breastfeeding (EBF) by 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Still breastfeeding at 3 months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: risk of reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative healing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 12-month cumulative relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: disease-free time from healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnosis of heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive impairment levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse responses to citalopram
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in CSF levels of DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in CSF levels of total and phosphorylated tau
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in soluble interleukin‐1 receptor type II levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from moderate or severe aortic regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NYHA functional class I or II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RQLQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WPAI-AS
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: childhood CRF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Cross-Sectional Area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in leg press strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in leg extension 1-RM loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of participants with moderate to severe symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay in the postanesthesia care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: C(max) and AUC(0‐t) values for parent idebenone and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events of mild to moderate severity
Endpoint domain: Adverse events/effects
Primary endpoint: visual symptomatology improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes